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OBJECTIVES: The FAME Study is an international multicenter randomized clinical
trial (n1,005), which proved a significant improvement in health outcomes for
patients undergoing multivessel percutaneous coronary intervention (PCI) guided
by fractional flow reserve (FFR) measurement compared to PCI guided by angiog-
raphy alone (ANGIO). The objective of this study is to estimate the impact of FFR-
guided PCI on public health and on healthcare budget in France and Belgium and to
compare these results with those of other European countries.METHODS:We used
original patient-level data of the FAME Study (Tonino et al., NEJM 2009) to estimate
health effects for France and Belgium. Utilities were measured with EQ-5D using
French (time trade-off based) and Belgian Torrance transformed (visual analogue
scale based) weights. Costs were based on French and Belgian prices and DRG
catalogues. The size of the population eligible for the intervention was taken from
national PCI registries to calculate number of major adverse cardiac events (MACE)
avoided, quality-adjusted life years (QALYs) gained, and cost savings during a
2-year budget period (2011-2012) from the payer’s perspective. We estimated
ranges based on best and worst case scenarios regarding benefits, costs and FFR
uptake. RESULTS: For both countries, FFR led to more QALYs, less MACE and lower
costs under different scenarios within 2-year time horizon. The public health im-
pact of implementing FFR-guided PCI ranged from 6 to 44 QALYs gained in France
and 12 to 234 in Belgium. MACEs avoided ranged from 284 to 2108 and from 23 to
467, respectively. Cost savings ranged from 4.8 to 28.9 and from 0.43 to 7.7 million
EUR, respectively. CONCLUSIONS: Our impact study shows that FFR-guided PCI in
patients with multivessel coronary disease is dominant and leads to considerably
reduced numbers of MACE, more QALYs and substantial cost savings in the French
and Belgian health care systems.
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OBJECTIVES: Sacral Neuromodulation (SNM) has proven to be an effective, safe and
cost-effective therapy that should be available for refractory Overactive Bladder
(OAB) and Fecal Incontinence (FI) patients. Canary Islands are divided into two
provinces: Las Palmas and Santa Cruz de Tenerife. Refractory OAB and FI patients
from Las Palmas are referred to other Spanish regions to receive SNM. This Budget
Impact Analysis (BIA) approaches two possible referral programs from the perspec-
tive of Canary Islands Health Service (CHS): the treatment of these patients in
Tenerife in a regional Center of Excellence or in Madrid as representative of the
mainland. METHODS: A BIA was developed to analyze the different direct costs
related to each of the options for a refractory population of 11 OAB and 4 FI patients
during 1 year. The net economic impact caused by the treatment of patients from
Las Palmas with SNM therapy was calculated based on two previous cost-effective-
ness models and was assumed to be similar in both cases. Costs related to hospi-
talization, travelling, and living expenses for the patient and the caregiver were
also considered, as these costs are reimbursed by the CHS to the patients and
caregivers. RESULTS: The net economic impact for the CHS of treating 15 new
patients from Las Palmas with SNM in Madrid would be €118,871 for the first year of
the therapy, while treating these patients in Tenerife’s Center of Excellence would
be related to a net impact of €50,780. The savings provided by a referral program
inside the Region would amount to €68,091; driven by differences in hospitaliza-
tion, travelling and living expenses. CONCLUSIONS: In Canary Islands, the desig-
nation of Regional Centers of Excellence for specialized and effective treatments,
such as SNM, would lead to important savings for the CHS, driven by differences in
hospitalization, travelling and living expenses due to referral programs.
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OBJECTIVES: The increasing penetration of endoscopic techniques in surgical pro-
cedures has resulted in a more frequent use of rigid endoscopes (RE). Several stud-
ies have reported significant reductions in the number of damaged RE and repairs
when reprocessed with Sterrad™ instead of Steam. The aim of this study was to
analyze the economic consequences of RE sterilization with Sterrad™ versus
Steam from a hospital perspective. METHODS: A dynamic excel-based decision-
analytic model was developed. Published literature was used to estimate the two
key variables (% of RE damage with Steam as well as with Sterrad™). A two-way
sensitivity analysis was conducted (varying the two key variables up to25%, thus
generating 121 different scenarios). Input data for the model collected as an aver-
age from four Spanish hospitals were: 1000 RE sterilization units (StU) annually,
2000€ cost for every RE repair and 0,56€ in consumables/StU with Steam. 11,99€ in
consumables/StU with Sterrad™ was calculated based on list prices and an average
of 2.5 RE per sterilization cycle. The analysis covered a one year time horizon and
assumed 100% utilization for each sterilization technology.RESULTS:A 21% budget
impact decrease was achieved with Sterrad™ versus Steam, leading to 11,870€ in
annual savings. The more costly sterilization process (11,986€ versus 560€ per year)
was clearly more than compensated by the reduction of 23,296€ in RE repair costs.
The sensitivity analysis showed in 100% of the scenarios that Sterrad™ was cost-
saving compared to Steam.CONCLUSIONS:This analysis adds a new component of
support for the sterilization of rigid endoscopes with Sterrad™ by demonstrating
that it is cost-saving compared to reprocessing with Steam. Despite the conserva-
tive approach of the model which may be in favour of Steam, use of Sterrad™ led to
savings of 21% in the hospital budget.
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OBJECTIVES: Recent literature suggests complication rates associated with current
VCDs are comparable or reduced when compared to manual compression (MC).
However, well-documented differences exist among VCDs regarding the type and
magnitude of complications. An indirect comparison was conducted to estimate
the cost savings associated with use of novel VCD EXOSEAL™ vs. VCDs ANGI-
OSEAL™, MYNX™, PERCLOSE™ and STARCLOSE™ from the US hospital system
perspective.METHODS: Crude VCD-specific complication rates were calculated for
occlusion, access-site infection (ASI), femoral pseudoaneurysm (FAP), retroperito-
neal hemorrhage (RPH), other access-site bleeds (OASB), and arteriovenous fistula
(AVF) using prospective clinical studies identified in the most recent VCD instruc-
tions for use. A literature review (i.e., 2005 to current) was conducted to identify
rates of complication consequences (i.e., amputation, vascular surgery, endovas-
cular procedure, transfusion, ultrasound-guided intervention) and associated US
costs were then applied to clinical consequence rates. The one-year budget impact
was estimated assuming 100% use of EXOSEALTM vs. current VCD market-share for
percutaneous coronary intervention (PCI) procedures. Device costs were assumed
identical. RESULTS: Complication rates for occlusion, ASI, RPH, FAP, OASB, and
AVF were calculated for each VCD as follows: EXOSEALTM [0.00%, 0.00%, 0.56%,
0.00%, 0.00%, 0.00%], ANGIOSEALTM [0.33%, 0.00%, 0.33%, 0.00%, 0.00%, 0.33%], MY-
NXTM [0.00%, 0.00%, 0.00%, 0.53%, 0.53%, 0.00%], PERCLOSETM [0.00%, 0.78%, 0.52%,
0.26%, 0.52%, 0.00%] and STARCLOSETM [0.20%, 0.00%, 0.00%, 0.20%, 0.41%, 0.00%].
Results predicted that 100% use of EXOSEALTM vs. combined use of VCDs could save
approximately $70 USD per procedure and approximately $70,240 USD per 1,000
annual PCI procedures (i.e., typical hospital). Assuming 550,000 PCIs that use VCDs
annually in the US, this translates to a predicted yearly cost-savings of $38,631,949
USD for the US hospital system. CONCLUSIONS: This analysis suggests use of
EXOSEAL™ in patients undergoing PCI procedures may result in important cost-
savings for US hospitals. Additional data will be required to confirm low complica-
tion rates with EXOSEAL™.
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OBJECTIVES: The presence of diabetes in patients needing percutaneous coronary
intervention (PCI) is associated with increased risk of adverse outcomes, such as
target lesion revascularization (TLR), and thus an additional cost burden. A recent
indirect treatment comparison (ITC) showed that the drug-eluting stent (DES)
CYPHER™ improved clinical outcomes vs other DES resulting in cost-savings in
diabetic patients. Based on this ITC, the objective is to conduct an adaptation to
Spain and compare CYPHER vs. XIENCE™ from a hospital perspective with global
annual budget. METHODS: A global budget-impact model was adapted to Spain
using a previously reported ITC of DES in diabetic patients. In brief, the ITC in-
cluded pair-wise meta-analyses of randomized trials with a common comparator
to obtain relative treatment effects for different DES and absolute TLR risk. These
reported clinical estimates were added to the Spain model, along with reported use
and reimbursement rates for diagnosis-related groups (DRGs) of index procedures
and re-interventions in Spain. Budget-impact was estimated for 100 annual PCIs
with DES for diabetic patients in a typical Spanish hospital, assuming 100% utili-
zation for each stent and identical stent acquisition cost. Analyses were conducted
using two methods for estimating TLR risk. RESULTS: Results predicted that
CYPHER, if used instead of XIENCE, could save approximately 320€ to 407€ per
diabetic patient annually depending on TLR risk estimation method. Assuming 100
annual PCIs in diabetic patients, this translates to cost-savings varying from
32,048€ to 40,710€. These savings are driven by reduction in secondary interven-
tions achieved by choosing the DES with the best TLR outcomes. CONCLUSIONS:
This analysis indicates that use of CYPHER versus XIENCE in diabetic patients
undergoing PCI can produce important savings for hospitals. Further cost research
and clinical expert validation are needed to confirm results of this local adaptation.
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